| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Katarina Melo Chaves, Antoni Serrano-Blanco, Susana Barbosa Ribeiro, Luiz Alberto Lira Soares, Gerlane Coelho Bernardo Guerra, Maria do Socorro Costa Feitosa Alves, Raimundo Fernandes de Araújo Júnior, Vanessa de Paula Soares Rachetti, Antônio Filgueira Júnior, Aurigena Antunes de Araúj. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. The Psychiatric quarterly. vol 84. issue 1. 2013-07-22. PMID:22806578. |
quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. |
2013-07-22 |
2023-08-12 |
Not clear |
| Katarina Melo Chaves, Antoni Serrano-Blanco, Susana Barbosa Ribeiro, Luiz Alberto Lira Soares, Gerlane Coelho Bernardo Guerra, Maria do Socorro Costa Feitosa Alves, Raimundo Fernandes de Araújo Júnior, Vanessa de Paula Soares Rachetti, Antônio Filgueira Júnior, Aurigena Antunes de Araúj. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. The Psychiatric quarterly. vol 84. issue 1. 2013-07-22. PMID:22806578. |
this cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (qol) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of hospital dr. joão machado, natal, rio grande do norte, brazil. |
2013-07-22 |
2023-08-12 |
Not clear |
| Edoardo Spina, Rosalia Crup. Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia. Journal of central nervous system disease. vol 3. 2013-07-17. PMID:23861636. |
additional active comparator trials evaluating efficacy, tolerability and cost-effectiveness are required to better define the role of paliperidone er in the treatment of schizophrenia in relation to other currently available second-generation antipsychotics, particularly risperidone. |
2013-07-17 |
2023-08-12 |
Not clear |
| Rosa Catalán, Rafael Penadé. Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia. Journal of central nervous system disease. vol 3. 2013-07-17. PMID:23861642. |
risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia. |
2013-07-17 |
2023-08-12 |
Not clear |
| Rosa Catalán, Rafael Penadé. Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia. Journal of central nervous system disease. vol 3. 2013-07-17. PMID:23861642. |
current scientific literature revealed that long-acting risperidone is effective in treating the positive and negative symptoms of schizophrenia and some improvements in cognition and functioning have also been found. |
2013-07-17 |
2023-08-12 |
Not clear |
| b' Zofia Rog\\xc3\\xb3\\xc5\\xb. Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacological reports : PR. vol 64. issue 6. 2013-07-16. PMID:23406768.' |
effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. |
2013-07-16 |
2023-08-12 |
mouse |
| b' Zofia Rog\\xc3\\xb3\\xc5\\xb. Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacological reports : PR. vol 64. issue 6. 2013-07-16. PMID:23406768.' |
several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia. |
2013-07-16 |
2023-08-12 |
mouse |
| Parthasarathy Ramamourthy, Arunkumar Kumaran, Shivanand Kattiman. Risperidone associated paralytic ileus in schizophrenia. Indian journal of psychological medicine. vol 35. issue 1. 2013-07-08. PMID:23833349. |
risperidone associated paralytic ileus in schizophrenia. |
2013-07-08 |
2023-08-12 |
Not clear |
| Parthasarathy Ramamourthy, Arunkumar Kumaran, Shivanand Kattiman. Risperidone associated paralytic ileus in schizophrenia. Indian journal of psychological medicine. vol 35. issue 1. 2013-07-08. PMID:23833349. |
risperidone is said to be devoid of anticholinergic side effects, but prevalence of these varies from 7% to 13% in patients receiving treatment for schizophrenia. |
2013-07-08 |
2023-08-12 |
Not clear |
| Amrita Prakash Singam, Abhishek Mamarde, Prakash B Beher. A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia. Indian journal of psychological medicine. vol 33. issue 2. 2013-07-04. PMID:22345836. |
a single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia. |
2013-07-04 |
2023-08-12 |
Not clear |
| Amrita Prakash Singam, Abhishek Mamarde, Prakash B Beher. A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia. Indian journal of psychological medicine. vol 33. issue 2. 2013-07-04. PMID:22345836. |
the present study was undertaken to test the comparative efficacy of chlorpromazine and risperidone in patients of schizophrenia in a tertiary care hospital of maharashtra. |
2013-07-04 |
2023-08-12 |
Not clear |
| Amirhossein Modabbernia, Farzin Rezaei, Bahman Salehi, Morteza Jafarinia, Mandana Ashrafi, Mina Tabrizi, Seyed M R Hosseini, Masih Tajdini, Ali Ghaleiha, Shahin Akhondzade. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23233269. |
intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. |
2013-07-03 |
2023-08-12 |
Not clear |
| Ronald Diamon. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia. Evidence-based mental health. vol 16. issue 1. 2013-06-28. PMID:23232810. |
long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia. |
2013-06-28 |
2023-08-12 |
Not clear |
| Tomomi Tenjin, Seiya Miyamoto, Yuriko Ninomiya, Rei Kitajima, Shin Ogino, Nobumi Miyake, Noboru Yamaguch. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatric disease and treatment. vol 9. 2013-06-24. PMID:23766647. |
in several short-term double-blind clinical trials, blonanserin had equal efficacy as haloperidol and risperidone for positive symptoms in patients with chronic schizophrenia and was also superior to haloperidol for improving negative symptoms. |
2013-06-24 |
2023-08-12 |
Not clear |
| Jérôme Lerond, Amélie Lothe, Philippe Ryvlin, Sandrine Bouvard, Thierry d'Amato, Carolina Ciumas, Jean Daléry, Emmanuel Poulet, Mohamed Saou. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. Journal of clinical psychopharmacology. vol 33. issue 1. 2013-06-12. PMID:23277246. |
effects of aripiprazole, risperidone, and olanzapine on 5-ht1a receptors in patients with schizophrenia. |
2013-06-12 |
2023-08-12 |
human |
| Robin Emsley, Petrus Oosthuizen, Liezl Koen, Dana Niehaus, Lupe Martine. Comparison of treatment response in second-episode versus first-episode schizophrenia. Journal of clinical psychopharmacology. vol 33. issue 1. 2013-06-12. PMID:23277247. |
the sample comprised 31 participants who (1) had successfully completed a 2-year open-label treatment phase with risperidone long-acting injection (rlai) for a first episode of schizophrenia; (2) underwent an intermittent treatment extension phase up to 3 years or until recurrence, and (3) entered a further 2-year treatment phase with rlai for a recurrence episode. |
2013-06-12 |
2023-08-12 |
human |
| Geeta Aggarwal, Sanju Dhawan, S L Hari Kuma. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug development and industrial pharmacy. vol 39. issue 1. 2013-06-10. PMID:22335586. |
the efficacy of oral risperidone treatment in prevention of schizophrenia is well known. |
2013-06-10 |
2023-08-12 |
rat |
| Geeta Aggarwal, Sanju Dhawan, S L Hari Kuma. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug development and industrial pharmacy. vol 39. issue 1. 2013-06-10. PMID:22335586. |
this suggests the transdermal application of risperidone holds promise for improved bioavailability and better management of schizophrenia in long-term basis. |
2013-06-10 |
2023-08-12 |
rat |
| Marcela Horvitz-Lennon, Margarita Alegría, Sharon-Lise T Norman. The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia. Psychiatric services (Washington, D.C.). vol 63. issue 12. 2013-06-10. PMID:23026838. |
this study evaluated the effect of race-ethnicity and geography on the adoption of a pharmacological innovation (long-acting injectable risperidone [lair]) among medicaid beneficiaries with schizophrenia as well as the contribution of geographic location to observed racial-ethnic disparities. |
2013-06-10 |
2023-08-12 |
Not clear |
| Arghya Dutta, Supartha Barua, Amitava Dan, Kaustav Chakraborty, Manas Manda. Iloperidone-induced Galactorrhea in a Middle-aged Female. Indian journal of psychological medicine. vol 34. issue 4. 2013-06-03. PMID:23723555. |
iloperidone, a piperidinyl-benzisoxazole derivative, is structurally related to risperidone and approved for treatment in acute stage of schizophrenia. |
2013-06-03 |
2023-08-12 |
Not clear |